Baseline significant tricuspid regurgitation is associated with higher mortality in transcatheter aortic valve replacement: systemic review and meta-analysis
- PMID: 31593560
- DOI: 10.2459/JCM.0000000000000807
Baseline significant tricuspid regurgitation is associated with higher mortality in transcatheter aortic valve replacement: systemic review and meta-analysis
Abstract
Introduction: Significant tricuspid regurgitation is a well recognized indicator of right ventricular dysfunction. Recent studies have shown that significant tricuspid regurgitation is potentially associated with increased mortality in patients with severe aortic stenosis who underwent transcatheter aortic valve replacement (TAVR). However, data remained sparse and inconclusive. Thus, we performed a systematic review and meta-analysis of the literature to assess the association between significant tricuspid regurgitation and mortality in post TAVR patients.
Hypothesis: Significant tricuspid regurgitation is predictive for higher mortality in patients undergoing TAVR.
Methods: We comprehensively searched the databases of MEDLINE and EMBASE from inception to October 2018. Included studies were published observational studies that reported multivariate analysis of the effects of significant tricuspid regurgitation on all-cause mortality among patients undergoing TAVR. Data from each study were combined utilizing the random-effects, generic inverse variance method of DerSimonian and Laird to calculate odds ratios (ORs) and 95% confidence intervals (CIs).
Results: Nine cohort studies from August 2011 to May 2018 consisting of 27 614 patients with severe aortic stenosis undergoing TAVR (6255 with and 21 359 without significant tricuspid regurgitation) were included in this meta-analysis. The presence of significant tricuspid regurgitation was associated with higher all-cause mortality (pooled OR = 2.26, 95% CI: 1.45-3.52, P < 0.001). We found that all-cause mortality remained statistically substantial in all subgroups (30-day all-cause mortality: OR = 2.05, 95% CI: 1.20-3.49, P = 0.009; midterm all-cause mortality: OR = 9.67, 95% CI: 2.44-38.31, P = 0.001; and long-term all-cause mortality: OR = 1.48, 95% CI: 1.19-1.85, P < 0.001). Funnel plots and Egger's regression asymmetry test were performed and showed no publication bias.
Conclusion: Significant tricuspid regurgitation increased risk of mortality by up to two-fold among patients with severe aortic stenosis undergoing TAVR. Our study suggests that significant tricuspid regurgitation should be considered a component of risk stratification tools.
Similar articles
-
Impact of Tricuspid Regurgitation on Outcomes of Transcatheter Aortic Valve Replacement With Balloon-Expandable Valves.JACC Cardiovasc Interv. 2024 Aug 26;17(16):1916-1931. doi: 10.1016/j.jcin.2024.07.005. JACC Cardiovasc Interv. 2024. PMID: 39197990
-
Impact of Tricuspid Valve Regurgitation on Early Outcomes after Transcatheter Aortic Valve Replacement.J Heart Valve Dis. 2017 Jul;26(4):380-385. J Heart Valve Dis. 2017. PMID: 29302936
-
Prognostic Assessment of Right Ventricular Systolic Dysfunction on Post-Transcatheter Aortic Valve Replacement Short-Term Outcomes: Systematic Review and Meta-Analysis.J Am Heart Assoc. 2020 Jun 16;9(12):e014463. doi: 10.1161/JAHA.119.014463. Epub 2020 Jun 10. J Am Heart Assoc. 2020. PMID: 32517527 Free PMC article.
-
Impact of concurrent tricuspid regurgitation on mortality after transcatheter aortic-valve implantation.Catheter Cardiovasc Interv. 2019 Apr 1;93(5):946-953. doi: 10.1002/ccd.27948. Epub 2018 Nov 25. Catheter Cardiovasc Interv. 2019. PMID: 30474201 Review.
-
Previous coronary artery bypass graft is not associated with higher mortality in transcatheter aortic valve replacement: systemic review and meta-analysis.Acta Cardiol. 2020 Feb;75(1):26-34. doi: 10.1080/00015385.2018.1541845. Epub 2019 Jan 16. Acta Cardiol. 2020. PMID: 30650054
Cited by
-
One-Year Outcome of Patients Undergoing Transcatheter Aortic Valve Replacement with Concomitant SignificantTricuspid Regurgitation.J Cardiovasc Dev Dis. 2025 May 14;12(5):184. doi: 10.3390/jcdd12050184. J Cardiovasc Dev Dis. 2025. PMID: 40422955 Free PMC article.
-
Bioprosthetic Valves for Lifetime Management of Aortic Stenosis: Pearls and Pitfalls.J Clin Med. 2023 Nov 13;12(22):7063. doi: 10.3390/jcm12227063. J Clin Med. 2023. PMID: 38002679 Free PMC article. Review.
-
Prognostic Value of the Tricuspid Regurgitation Impact on Outcomes (TRIO) Score in Patients Undergoing Transcatheter Aortic Valve Implantation.Rev Cardiovasc Med. 2025 Jan 21;26(1):26504. doi: 10.31083/RCM26504. eCollection 2025 Jan. Rev Cardiovasc Med. 2025. PMID: 39867186 Free PMC article.
-
Tricuspid Regurgitation and Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis.Arq Bras Cardiol. 2023 Aug 7;120(7):e20220319. doi: 10.36660/abc.20220319. eCollection 2023. Arq Bras Cardiol. 2023. PMID: 37556650 Free PMC article. English, Portuguese.
-
Functional tricuspid regurgitation, related right heart remodeling, and available treatment options: good news for patients with heart failure?Heart Fail Rev. 2022 Jul;27(4):1301-1312. doi: 10.1007/s10741-021-10141-6. Epub 2021 Jul 15. Heart Fail Rev. 2022. PMID: 34264478 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources